Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition

Inclusion criteria: * Men and women with type 2 diabetes that will need enteral nutrition with carbohydrate content. * Glycemia \>140mg/dL and \< 400mg/dL at admission on the ward. * Informed consent (patient or legally authorized representative) Exclusion criteria: * Hypersensibility to insulin glargine or glulisine, or any other component of the insulin formulation. * Use of investigational medications during the last 12 months or use of any investigational insulin preparation during the last 4 months. * History of diabetic ketoacidosis or hyperosmolar hyperglycaemic state or ketonuria. * Subjects with conditions that are expected to need surgery or intensive care unit (ICU)admission based on discussions with the treatment team and attending physician. * Pregnancy. * Severe hepatic disease or active hepatitis. * Cardiac failure class III or IV (Classification de la New York Heart Association:NYHA). * Diagnosed advanced autonomic neuropathy. * Diagnosed cancer. * Active infection. * Current therapy with steroids. * Patients with recognized or suspected endocrine disorders associated with increased insulin resistance, acromegaly, or hyperthyroidism. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.